05:48 PM EDT, 08/13/2024 (MT Newswires) -- Zevra Therapeutics ( ZVRA ) posted a Q2 net loss late Tuesday of $0.48 per diluted share, compared with a loss of $0.08 a year ago.

Analysts polled by Capital IQ expected a loss of $0.44.

Revenue for the quarter that ended June 30 was $4.45 million, down from $8.47 million a year earlier.

Analysts surveyed by Capital IQ expected $4.36 million.

Price: 6.70, Change: -0.08, Percent Change: -1.18